RAFLF (Raffles Medical Group) Research & Development: $0.0 Mil (TTM As of Dec. 2025)


RAFLF Raffles Medical Group Ltd RAFLF
57 GF Score
Price $0.75
GF Value $0.75
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Raffles Medical Group Research & Development?

Raffles Medical Group RAFLF 57 Research & Development is $0.0 Mil as of Dec. 2025. GuruFocus rates RAFLF with a GF Score™ of 57/100 and a GF Value™ of $0.75 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Raffles Medical Group's Research & Development for the six months ended in Dec. 2025 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $0.0 Mil.

Raffles Medical Group  (OTCPK:RAFLF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Raffles Medical Group Research & Development Related Terms

Raffles Medical Group Research & Development Historical Data

* Premium members only.

The historical data trend for Raffles Medical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Raffles Medical Group Research & Development Chart

Raffles Medical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Raffles Medical Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RAFLF
57GF Score
Raffles Medical Group Ltd RAFLF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Raffles Medical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.0 Mil mean?
Raffles Medical Group (RAFLF) has a Research & Development of $0.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Raffles Medical Group and its competitors.
Is Raffles Medical Group's Research & Development too high?
Raffles Medical Group's current Research & Development is $0.0 Mil. Overall, Raffles Medical Group has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Raffles Medical Group's Research & Development compare to HCA and THC?
Raffles Medical Group's Research & Development of $0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Raffles Medical Group and its competitors. Raffles Medical Group's current Research & Development is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Raffles Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Raffles Medical Group (RAFLF) is currently considered Fairly Valued. The stock's GF Value™ is $0.75, compared to a current price of $0.75 — trading 0.4% above its estimated fair value. The current Research & Development is $0.0 Mil. Raffles Medical Group's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Raffles Medical Group (RAFLF), the current Research & Development is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Raffles Medical Group (RAFLF) Overvalued in 2026?

Based on GuruFocus' analysis, Raffles Medical Group stock appears to be overvalued. The current stock price of $0.75 is trading 0.4% above its estimated GF Value™ of $0.75. GuruFocus considers Raffles Medical Group to be Fairly Valued.

Key valuation signals for RAFLF:

  • Research & Development: $0.0 Mil
  • GF Value™: $0.75 vs. price of $0.75 (0.4% above fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the RAFLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Raffles Medical Group Business Description

Other Exchanges BSL:Singapore
Address 585 North Bridge Road, No. 11-00, Raffles Hospital, Singapore, SGP, 188770
Raffles Medical Group Ltd is an integrated private healthcare provider in Asia with operations in Singapore, China, Japan, Vietnam, and Cambodia. The company owns and operates a tertiary hospital, a network of medical and dental clinics, insurance services, Japanese and Traditional Chinese Medicine clinics, and a consumer healthcare division. The company's operating segment includes Healthcare services, Hospital Services, Investment Holdings, and Insurance Services. The company generates revenue from contracts with customers, Rental Income, and Insurance revenue. Geographically operates in Singapore, Greater China, Vietnam, Cambodia and Japan.
57GF Score

Get the complete analysis for RAFLF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price
$0.75
GF Value